Immunai is a company headquartered at 430 E 29th St, New York, NY 10016, USA[2] that focuses on mapping the immune system at single-cell scale[1]. The company employs machine learning technology and maintains AMICA, described as the world's largest immune-focused harmonized single-cell database[1]. Immunai's stated mission involves facilitating the development of next-generation immune-related therapeutics through its platform[1].
Something wrong or missing? Send a correction. Fixed within 24 hours.